Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dronabinol for Pain in Sickle Cell Disease
NCT03978156Phase 1Terminated
- Sponsor
- Yale University
- Start
- Jul 2019
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of dronabinol in sickle cell disease (SCD) (2 arms), sponsored by Yale University. Primary endpoints: Feasibility defined by ability to mask patients and investigators and adherence at 1 year, Adherence to study medication at 1 year and 1 more. Started Jul 2019; status: terminated.
02
Drugs
dronabinol
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT03978156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03978156.